BalamirIAtesITopcuogluCTurhanT. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2017;69:609–16.
2.
YilmazMISiriopolDSaglamM, et al.Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86:1213–20.
3.
ChawlaRLoombaRGuruDLoombaV. Ischemia modified albumin (IMA)—a marker of glycaemic control and vascular complications in type 2 diabetes mellitus. J Clin Diagn Res. 2016;10:BC13–16.
4.
ÇavuşoğluYKorkmazŞDemirtaşS, et al.Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study. Anatol J Cardiol. 2015;15:611–7.
5.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339–43.
6.
BaltaSMikhailidisDPDemirkolS, et al.Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65:773–7.
7.
BolatkaleMDugerMÜlferG, et al.A novel biochemical marker for community-acquired pneumonia: ischemia-modified albumin. Am J Emerg Med. 2017;35:1121–5.
8.
BaldassarreMPAAndersenAConsoliAKnopFKVilsbøllT. Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes Obes Metab. 2018;20:1350–60.
9.
BalciKGBalciMMSenF, et al.The role of baseline indirect inflammatory markers in prediction of response to cardiac resynchronisation therapy. Kardiol Pol. 2016;74:119–26.
10.
YilmazSAkbogaMKArasDTopalogluS. Evaluation of the predictive value of CHA(2)DS(2)-VASc score for in-stent restenosis. Angiology. 2018;69:38–42.
